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Primary extra-gastrointestinal stromal tumor (EGISTs) arising in the pancreas is extremely rare: only 20 cases have
previously been reported in the English literature from 2000 to 2013. We reported a case of EGIST of the pancreas in a
69-year-old woman who presented with abdominal pain and with a solid, heterogeneously enhancing neoplasm in the
uncinate process of the pancreas, revealed preoperatively by an abdominal computed tomography scan. A diagnosis of
neuroendocrine tumor was suggested. Positron emission tomography with 68Ga-DOTATOC did not show pathological
accumulation of the tracer in the pancreas. The patient underwent enucleation, under ultrasonic guidance, of the
pancreatic tumor that emerged to the surface of the pancreas. Histopathology and immunohistochemical examination
confirmed the final diagnosis of EGIST of the pancreas (CD117+), with one mitosis per 50 high-power fields. Although
rarely, GIST can involve the pancreas as a primary site, and this tumor should be considered in the differential diagnosis
of pancreatic neoplasms.
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Gastrointestinal stromal tumors (GIST) are the most com-
mon mesenchymal tumors of the gastrointestinal tract,
with an annual incidence of 10 to 20 per million [1]. GISTs
are neoplasms arising from, or differentiating along, a line
similar to the gastrointestinal pacemaker cells, the intersti-
tial cells of Cajal (ICCs) [2-4]. ICCs form a network around
the myenteric plexus and within the muscolaris propriae of
the gastrointestinal wall. GISTs may occur in the entire
length of gastrointestinal tract from the esophagus to the
anus; however, the most common sites are stomach (60%),
small intestine (30%), rectum (5%), and esophagus (<5%)
[1]. Duodenal GISTs constitute 30% of primary duodenal
tumors and less than 5% of gastrointestinal stromal tumors
[5-7]. Sometimes, these tumors may arise from the omen-
tum, mesentery, gallbladder, and retroperitoneum, adja-
cent, but separate from the stomach and the intestine
[8-10]; in this case the neoplasm is defined as ‘extra-gastro-
intestinal stromal tumors’ (EGISTs). EGISTs do not display
connection to the wall or the serosal surface of the viscera.
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unless otherwise stated.20 cases have been reported in the literature from 2000 to
2013 [11-31]. We present a new case of a pancreatic EGIST
misinterpreted as non-functioning endocrine tumor, in a
69-year-old woman. A review of the literature is also
included.Case presentation
A 69-year-old woman presented in March 2013 with ab-
dominal pain localized in the right hyphocondrium.
There was no history of vomiting, gastrointestinal bleed-
ing, jaundice, anorexia, or weight loss. Abdominal ultra-
sonography did not show pathologic features, but the
pancreas was not clearly visualized. Contrast-enhanced
computed tomography (CT) of the abdomen (Figure 1)
revealed a solid, hypervascular nodule in the uncinate
process of the pancreas, measuring 22 × 15 mm. The
possibility of a neuroendocrine tumor was considered;
therefore she underwent Gallium-68 somatostatin recep-
tor positron emission tomography (PET) (68Ga-DOTA-
TOC), without evidence of neoplasms with pathologic
expression of somatostatin receptors. Routine laboratory
investigations, exocrine and endocrine serum markers,
and hormonal panel were within normal limits, except
for CEA: 5.7 ug/L ( reference value <5 ug/L). Endoscopic
ultrasound (EUS) confirmed a 2-cm hypoechoic tumoral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Abdominal CT scan showing a 2-cm, contrast-enhanced
mass (arrow) in the uncinate process of the pancreas.
Figure 2 Stromal tumor composed of spindle and epithelioid
cells with focal vacuolar (signet ring) change. (E & E, 20×).
Figure 3 Immunostain for c-KIT: strong and diffuse
cytoplasmic immunoreactivity.
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the lesion was not available at that moment. At laparot-
omy, in April 2013, a well-demarcated, red nodule was
identified in the uncinate process of the pancreas; no at-
tach with the duodenal wall was found. Intraoperative
sonography showed that the 2-cm hypoechoic mass was
separated from the main pancreatic duct. Careful enu-
cleation of the tumor with Harmonic scalpel, under
ultrasound guidance, was successfully performed. Pan-
creatic capsula was closed with interrupted, absorbable
stitches. The postoperative course was uneventful, and
the patient was discharged 7 days after surgery. Macro-
scopic examination showed a 2.4 cm well defined, ovoid
mass. Microscopically, the tumor was composed of spindle
cells, with focal atypia (Figure 2). The mitotic count was
one mitoses/50 high power fields (HPFs). Immunohisto-
chemical examination showed neoplastic cells diffusely
positive for antibodies against CD 117 (Figure 3), focally
positive for CD34 (Figure 4) and smooth muscle actin,
while cells were negative for desmin. A diagnosis of pan-
creatic GIST with low risk of malignancy has been placed,
pT2N0M0, stage I according to TNM (AJCC) classifica-
tion [32]. On molecular genetic examination, deletion of
three nucleotides in exon 11 of c-Kit was found. She did
not receive any adjuvant therapy after surgery; 12 months
later she is in good general condition and there is no evi-
dence of recurrent disease.
Discussion
We reported a rare case of a primary pancreatic GIST:
the small size, the well circumscribed margins of the le-
sion, and the contrast enhancement at CT examinationsuggested a diagnosis of neuroendocrine tumor of the
pancreas. GISTs reported outside the gastrointestinal tract
as apparent primary tumors are defined as ‘extra-gastro-
intestinal stromal tumors’ (EGISTs). The concept of GIST
has recently been established, due to the progress in immu-
nohistochemical analyses. It is presumed that these tumors
originate from the interstitial cells of Cajal (ICCs), pace-
maker cells, which are present throughout the wall of the
gastrointestinal tract and which regulate the motility. ICCs
share many characteristics with EGISTs, including expres-
sion of CD117 and CD34 [2]. In fact, the most selective im-
munohistochemical markers differentiating GISTs from
true smooth muscle tumors is the expression of the c-Kit
receptor tyrosine kinase (CD117 antigen) in 95% of GISTs.
In 2004, Yamamoto et al. [31] reported that EGISTs show
similar KIT mutations of typical GISTs suggesting that
these tumors have a similar origin. However, at present the
origin of EGISTs remains controversial. Some authors
Figure 4 Immunostain for CD34: focal immunoreactivity.
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cursor cell of ICCs and the smooth muscle cells of the gut,
which may account for their growth within and outside the
gastrointestinal tract [33]. Other, simpler, explanation sug-
gests that EGISTs are in fact mural GISTs with extensiveTable 1 Clinicopathologic features, treatment, and outcome o
Author Year Age (years) Sex Site/Treatment
Neto et al. [11] 2004 67 F Body and tail/DP + Im
Yamaura et al. [12] 2004 54 F Tail/DP
Krska et al. [13] 2005 38 F Body and tail/DP
Daum et al. [14] 2005 70 F Head/PD + Imatinib
Showalter et al. [15] 2008 72 F Tail/DP
Yan et al. [16] 2008 47 M Uncinate process/NR
Yang et al. [17] 2008 55 M Body and Tail/DP + Im
Harindhanavudhi et al. [18] 2008 63 F Body/Cystojejunostom
Imatinib
Trablesi et al. [19] 2009 52 F Head/PD
Goh et al. [20] 2009 58 M Head/PD
Padhi et al. [21] 2010 42 F Body and tail/DP
Saif et al. [22] 2010 31 M Head/PD + Imatinib
Crisan et al. [23] 2010 61 M Tail
Joshi and Rustagi [24] 2010 84 M Whole pancreas/NOP
Rao et al. [25] 2011 40 M Head and body/PD +
Imatinib
Cecka et al. [26] 2011 74 F Tail/DP
Vij et al. [27] 2011 35 M Head/PD + Imatinib
Soufi et al. [28] 2012 39 M Head/PD + Imatinib
Kim et al. [29] 2012 55 M Tail/DP + Imatinib
Babu et al. [30] 2012 55 F Head/local resection
Present case 2013 63 F Uncinate process/enu
A = alive; DP = distal pancreatectomy; NA = not available; NED = not evidence of disextramural growth, resulting in eventual loss of their con-
nection with the gut wall [33].
Pancreatic GISTs are extremely rare. We collected only
21 cases (including our patient) from the English literature:
their clinicopathologic features and outcomes are summa-
rized in Table 1. The age of the patients ranges from 30 to
84 years, with a mean age of 55.0 years. The male:female
ratio was 10:11. Ten of 21 (48%) tumors occurred in the
head of the pancreas, five in the tail (34%), four involved
both body and tail (19%), and two occurred in the uncinate
process (%). EGIST rarely (n = 1.5%) involved the entire
pancreas [24]. There is a great variation in size (range, 2.4
to 34 cm). The mitotic count was <5/50 HPFs in eight
cases (38%) and >10/50 HPFs in four cases (19%). Molecu-
lar biology of EGIST has been investigated in only two re-
ports [14,22] and in our patient: two exhibited deletion of
base pairs in exon 11, and one showed DNA polymorph-
ism of L862L in exon 18 of c-KIT gene [22]. All but one
patient underwent surgery: one patient with metastatic
disease died 5 days after admission without operation.
One patient underwent palliative operation (cystojejunost-
omy) and the remaining 17 patients underwent pancreaticf EGISTs reported in the English literature
Size (cm) Mitotic count
(/50 HPF)
Follow-up, months
atinib 20 120; CD117(+) CD34(+) A, Relapse, 1
14 Few; CD117(−) CD34(+) A, NED, 30
17 1; CD117(−) CD34(+) A, NED, 30
10 2; CD117(+) CD34(−) A, NED, 6
7 3; CD117(+) CD34(−) A, NED, 27
2.4 3; CD117(+) CD34(−) NA
atinib NR NR; CD117(+) CD34(+) Relapse, 24,- A, NED,41
y + 16 <5; CD117(+) CD34(+) NA
10.5 6; CD117(+) CD34(+) A, NED, 10
9 >10; CD117(+); CD34 (−) A, NED, 60
35 6-8; CD117(+) CD34(+) A, NED, 10
8 48; CD117(+) CD34(−) A, Relapse, 9
34 NR A, NED, 3
34 NR; CD117(+) CD34(+) Dead day 5 of admission
6.5 8-10; CD117(+) CD34(+) Relapse, 24; A, NED 30
11 <5; CD117(+)CD34(+) A, NED, 66
6.5 12-15; CD117(+) CD34(−) Relapse, 24; A, NED 48
9 5; CD117(+) CD34(+) A, NED, 24
15.8 7; CD117(+) CD34(−) A, NED, 4
5 6-8; CD117(+); CD34 (+) A, NED, 11
cleation 2.4 1; CD117(+) A, NED, 6
ease; NOP = not operated; NR = not reported; PD = pancreaticoduodenectomy.
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resection, and one (our case) enucleation of the tumor.
Follow-up was available in 19 cases. Disease recurrence
following surgery was reported in five cases: three patients
underwent re-resection and are alive and free after 30, 41,
and 48 months, respectively. Overall, 18 patients are alive
with a median survival time of 17.5 months (range, 1 to
66 months). Despite the limited number of cases and the
short follow-up time, it appears that resection of pancre-
atic GISTS may offer a good prognosis, even in recurrent
disease.
The clinical presentation of EGISTs is variable, depend-
ing on the location and size of the tumors. The tumor
may even be found incidentally. The most frequent clinical
symptoms are: abdominal pain, ileus, bleeding, anemia,
and weight loss. Our patient presented with a small, solid,
hyperintense lesion resembling a neuroendocrine tumor.
A similar finding of small, solid tumor in the uncinate
process of the pancreas was reported by Yan et al. [16] in
a case of GIST diagnosed by EUS fine-needle aspiration
(FNA): unfortunately, biopsy was not available for our pa-
tient. Interestingly, 50% (11/21) of the reported cases
showed radiologic features of heterogeneously mass (nec-
rotic areas) or solid-cystic appearance; thus, problems in
differential diagnosis with cystic neoplasms of the pan-
creas could be arise. The accuracy of CT determination of
the pathological diagnosis of a pancreatic cystic lesion is
less than 50% [34,35], but endoscopic ultrasound-guided
FNA may be helpful for the diagnosis of pancreatic lesions
[36]. The diagnosis of GIST is based on histological, im-
munohistochemical, and molecular features. Microscopic-
ally, this tumor, consisted of spindle cell and epithelioid
cells. The cytologic differential diagnosis for these spindle
cell proliferations includes leiomyoma, schwannoma, fibro-
matosis, inflammatory fibroid polyps, and gastrointestinal
muscularis sampling [16]. Immunoistochemical positivity
of CD117 confirms the diagnosis of GIST. GISTs exhibitTable 2 Selected agents investigated in the management of G
Author Year Pts (n) Phase study Treatme
Demetri et al. [42] 2002 147 II Imatinib
Demetri GD et al. [43] 2006 312 III Sunitinib
Blanke et al. [44] 2008 746 III Imatinib
Imatinib
De Matteo et al. [45] 2009 713 III Imatinib/
Dubreuil et al. [46] 2009 30 II Masitinib
Sawaki et al. [47] 2011 35 II Nilotinib
Park et al. [48] 2011 31 II Sorafenib
Joensuu et al. [49] 2012 400 III Imatinib
OR = overall response; OS = overall survival; PFS = progression-free survival; RFS = rea broad spectrum of clinical behaviors, with some low-
risk lesions remaining stable for years, while others pro-
gress rapidly to metastatic disease. Various parameters
are proposed to predict the malignant potential of GIST,
such as tumor size, mitotic activity, tumor location, non-
radical resection, tumor rupture, peritoneal dissemination,
metastasis, and invasion into adjacent organs. National In-
stitute of Health (NIH) consensus criteria (Fletcher’s cri-
teria) [37] proposed risk stratification of tumor behavior
into risk categories of very low, low, intermediate, and high
risk of metastasis, based on its size and mitotic activity. Tu-
mors larger than 10 cm in size and with more than 10 mi-
toses per 50 HPF are at high risk of aggressive behavior
[33,37]. Standard treatment for primary GIST is complete
surgical resection with the aim to obtain negative micro-
scopic margins of resection [13,38,39]. Lymphatic spread of
GISTs is uncommon; therefore, a systematic lymph node
dissection is not a standard surgical management. In our
patient we performed a simple tumor’s enucleation because
of a preoperative diagnosis of neuroendocrine tumor. How-
ever, after discussion with oncologists, the small size of the
lesion and the low-risk according to previously reported
prognostic criteria [37], suggested that it was an adequate
operation, as reported in a recent study [40]. The patient is
alive and free of disease 1 year after operation. The surgical
management may offer primary surgery at the time of diag-
nosis, neoadjuvant chemotherapy followed by surgery, adju-
vant therapy after surgery, or debulking surgery in patients
with metastatic or advanced disease. Observation only was
recommended in case with R0 resection or low-risk GIST.
In recent decades, medical therapy for GIST is improved
(Imatinib, Sunitinib, Nilotinib, Sorafenib, Dovitinib, and so
on) and consequently disease-free survival after surgery is
also much improved: in fact, it is recommended in patients
with R1 or R2 resection [41]. The results of some clinical
trials [42-49] with targeted therapy of GIST are reported in
Table 2. Obviously, data about targeted therapy for EGISTIST
nt End point Outcome (% or median) P value
OR 81.6%
/placebo TTP 27.3 vs. 5.4 weeks <0.0001
400 mg/ PFS 18 vs. 20 months 0.13
800 mg OS 55 vs. 51 months 0.83





12mo/36mo RFS & OS 65.6% vs. 47.9% <0.0001
92.0% vs. 81.7% 0.019
currence-free survival; TTP = time to tumor progression.
Beltrame et al. World Journal of Surgical Oncology 2014, 12:105 Page 5 of 6
http://www.wjso.com/content/12/1/105are limited. In the review of the literature, among 19 high-
risk EGISTs, only nine cases (47%) received adjuvant Ima-
tinib therapy (Table 1).
Conclusion
In conclusion, we report a new case of EGIST arising from
the pancreas, misinterpreted as neuroendocrine tumor.
Despite its rarity, GIST should be kept in mind in the dif-
ferential diagnosis of primary tumors of the pancreas, es-
pecially when a hypervascular lesion, solid or cystic, is
lacking somatostatin receptors at PET examination. Rad-
ical resection of pancreatic GISTs is the treatment of
choice, and repeat surgery for recurrence may offer a pro-
longed survival.
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